Shanghai Jmt-bio Inc.

This study tests a new drug combination (KN026 plus chemotherapy with or without enlonstobart) against the standard treatment for advanced HER2-positive stomach cancer that cannot be removed by surgery. About 490 adults will take part to see which approach shrinks tumors better a…

This study tests a new drug called JSKN003 against the usual combination of trastuzumab, pertuzumab, and docetaxel for people with HER2-positive breast cancer that has returned or spread. About 60 adults who have not had prior treatment for advanced disease will take part. The go…

This study tests a new drug called JSKN003 in people with advanced HER2-positive colorectal cancer that has not responded to standard chemotherapies. About 123 adults will receive either JSKN003 or a treatment chosen by their doctor. The goal is to see if JSKN003 can slow cancer …

This study tests a new drug called SYS6090 combined with chemotherapy or other targeted drugs in people with advanced lung cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors. About 596 adults aged 18 to 75 with non-smal…